

Life Sciences Caucus Meeting  
June 16, 2026  
7:30am


Co-chairs:

Senators Sawrey and Chaudhuri  
Representatives White and Reives

Meeting will begin shortly

# Agenda


- Welcoming remarks by Chairs
- Company presentations
  - Ten63 Therapeutics, Marcel Frankel, PhD, Co-Founder and CEO
  - The Traits Company, Fayaz Khazi, PhD, Founder and CEO
- Q&A



**TEN**<sup>63</sup>  
THERAPEUTICS

At Ten63 We are Building a Future  
Where No Loved One is Lost to Disease

# No One Has Yet Found The Path to Drug Discovery Superintelligence




We Have “Broken” Through  
by Making Simulations Indistinguishable From Reality **Impossible**




# BEYOND is The Most Accurate Simulation

Graph shows error distribution by method for nearly 5600 systems




\*SQM2.20 has repeatedly outperformed Schrödinger (SDGR), BOLTZ-2 and other top methods

# Early **BEYOND** is Making Breakthroughs




## Myc (Cancer)

Discovered nanomolar direct Myc inhibitors. Outperform top molecules from the previous 40 years of industry and academic research on inhibiting Myc.




## ROCK (Alzheimer's)

Discovered novel ROCK inhibitors that are more potent than an FDA approved drugs in biochemical assays.




## DDR1/2 (Cancer/Fibrosis)

Discovered the first DDR 1/2 degrader. Highly specific and potent molecules developed within 4 months. Demonstrating over 80% target degradation in animals.



## KRasG12D (Cancer)

Developed resistance-resilient molecules capable of killing cell lines resistant to gen-1 KRasG12D inhibitors.



## p53 (Cancer)

Outperformed current clinical candidate in cellular potency.

and More...

# Interdisciplinary Leadership Team Driving Our Mission




Marcel  
Frenkel, PhD  
Founder & CEO



Mark  
Hallen, PhD  
Founder & CTO




John  
Ketcham, PhD  
VP & Head of Chemistry




Charlie  
Holst, PhD  
VP & Head of Biology




Nate  
Guerin, PhD  
VP & Head of Engineering



Backed by Leading Early Investors





**TEN**<sup>63</sup>  
THERAPEUTICS



# **The Traits Company Inc.**

Founded in North Carolina; Feeding the World



- Traitology formed in **OCT 2022** with a \$25MM investment from GDM



2022

2023

- Research Ops started in **April 2023**
- Established Soybean Gene Editing Platform
- Target Discovery Platform initiated

- Facility expansion **April 2024**
- Target Discovery Platform completed
  - External Innovation integrated
- Rebranded as The Traits Company

2024

2025

- Expanded field ops
- Edited Soybean Lines in Field Testing
- Corn Projects Initiated



# Access to Market and Scale Through GDM

Soybean ↗



**45%**  
acres worldwide  
have GDM  
genetics

Corn ↗




**Growing investments** and  
commercial  
**development** in  
ARG, BRA, and NA.

Wheat ↗



**63%**  
of South America's  
Market Share

Sunflower ↗



# Access to a Global R&D Infrastructure

Through GDM, The Traits Company has access to scale, speed and strategic capital:

- Access to all the elite genetics
- Access to test sites in 15 countries on both hemispheres
- Access to expertise- breeding, agronomy, field and phenotyping
- Access to market insights- in USA, Brazil and Argentina

## Wide germplasm base

The germplasm is the basis of our improvement program. Our worldwide **presence** allows us to take maximum advantage from **genetic diversity**.

## Global scale and presence

We evaluate our germplasm in over **1.8 million plots /year in more than 700 areas in 15 countries**. This scale allows us to understand and know every environment and its interaction with our genetic base.

## High genetic profit rate

We are able to obtain **1 improvement cycle in less than 4 years** through multiple generations /year plus evaluations of early generations. This increases adaptability to environment changes and to new production systems.

# Integration of Technologies

to enhance genetic gain and the value of germplasm.

## BIOTECHNOLOGY

- Marker-Assisted Selection (MAS)
- Marker-Assisted Backcrossing (MABc)
- Gene Pyramiding
- Gene Discovery
- Purity Analysis
- Genome-Wide Selection (GWS)
- New Breeding Techniques (NBTs)

## PHYTOPATHOLOGY

- Greenhouse Test
- Field Test

## BREEDING

- Gene Introgression
- Cutting-edge experimental technology
- Hiring top talent through HR expertise

## ENGINEERING IN PROCESSES

- Process design
- Process control
- Logistics and operations

## INTEGRATED SYSTEM

- Global Software
- Mobile data collection

## DATA ANALYSIS

- Statistical analysis
- Decision making system

## IMAGE ANALYSIS

- Unmanned aerial vehicles (drones)
- GIS technology

**GERMPLASM**

# A

# BOLD

# VISION

# An R&D-Intensive Agbiotech's Perspective

- TraitsCo could have located anywhere globally. We chose RTP for talent, research ecosystem, proximity to universities— and accepted **higher operating costs and the absence of state R&D incentives** to do it.
- Federal law (IRC §174A, July 2025) now lets companies **immediately deduct domestic R&D**. NC, frozen at Jan 1, 2023 conformity, still forces R&D to be **capitalized and amortized over 5 years** on the state return. For a company whose spend is **overwhelmingly R&D** ( $\approx$ 30 scientists, lab + greenhouse, multi-year discovery pipeline), this defers deductions, **ties up working capital**, and raises after-tax cost of the exact activity NC wants to attract.
- The penalty falls hardest on **growth-stage, reinvestment-heavy** companies — the ones least able to absorb the cash-flow hit.
- Alternatives- **Missouri or Brazil?**

# R&D Tax Conformity Shows Policy Support

- **We are exactly the profile of the company that is meant to keep and grow in NC**
  - **Leverage high-skill jobs, collaborate locally, scale and grow.**
- **Conformity tells startups like us that NC's tax base moves *with* federal innovation policy, not against it.**
- **Conformity tells the world that North Carolina is *the* best place for Agbiotech**
- **Conformity underscores an innovation-centric mindset**

# Q&A

# Final Notes

---

1. R&D expense amortization
  - bad policy to tax phantom income
  - Anti-innovation
2. Omnibus Life Sciences Appropriation bill
3. Biomarker bill H567
  - Patient focused
  - Better decision making